ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2918

Do Patients with Lupus Nephritis Who Achieve Complete Proteinuria Recovery at 2 Years Have Better Long Term Outcomes Compared to Patients with Partial Proteinuria Recovery?

Zahi Touma1, Murray Urowitz2,3, Jorge Medina-Rosas4, Jiandong Su1 and Dafna Gladman1, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: outcomes, proteinuria and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The tempo of Complete Proteinuria Recovery (CPR) in Lupus Nephritis (LN) is slow and while 28% achieve CPR at year 1 this increases to 52% at year 2. The long term outcomes of patients who achieve CPR or Partial Proteinuria Recovery (PPR) of≥ 50% at 2 years is not well studied.

To determine the prognostic value of PPR and CPR at 2 years on long term outcomes compared to patients who did not recover proteinuria ≥ 50% on the standard of care therapy.

Methods: All patients that are registered at a large lupus clinic from 1970–2015 were reviewed (n=1782) and patients with LN were identified. LN was defined as: Proteinuria ≥0.5g/24 hours or spot Urine Protein Creatinine Ratio≥ 0.6mg/mg on 2 consecutive occasions within one year. Patients who achieved PPR or CPR within 2 years and have at least 5 years of follow up since the onset of LN were studied.

Endpoints:CPR was defined as proteinuria <0.5g/24 hours or PCR<0.6 mg/mg at least on 2 occasions. PPR was a decrease of ≥50% but not to normal levels. Not recovered was defined as <50% improvement.

Long term outcomes:Death, eGFR<15, dialysis or kidney transplant, damage [SLICC Damage Index (SDI)] >0 and >3) and atherosclerotic events occurring after achieving PPR or CPR.

Analyses:Non-parametric tests, survival analyses and simple cox regression were used to study the effect of PPR/CPR on outcomes.

Results: 326 patients (85% F) with LN were studied. The age at LN onset was 34.56 ± 12.19 yrs and lupus duration at LN onset was 5.72 ± 6.71 yrs. Follow up duration from lupus nephritis was 14.97 ± 8.95 yrs.

 Endpoints at 2 years: 178 had CPR, 43 PPR and 105 did meet the endpoints.

The prevalence of comorbidities(except damage) was the lowest in the CPR group, slightly higher in the PPR group and the highest in the no remission group (table 1).

Although CPR protects against the development of comorbidities (death, end stage kidney disease, dialysis and transplant, and atherosclerosis), PPR does not.   Damage accrual was not protected by CPR or PPR.

Table 1. Long term outcomes among 3 groups 

Outcomes

No remission

N = 105

(n and %)

PPR

N = 43

(n and %)

CPR

N = 178

(n and %)

Death

25 (23.8)

7 (16.3)

21 (11.8)

eGFR < 15

17 (16.2)

9 (20.9)

10 (5.6)

Dialysis or Transplant

15 (14.3)

8 (18.6)

10 (5.6)

SDI > 0

86 (81.9)

36 (83.7)

129 (72.5)

SDI > 3

30 (28.6)

20 (46.5)

44 (24.7)

Atherosclerotic Events

22 (20.9)

5 (11.6)

21 (11.8)

 Table 2. Effects of CPR and PPR on long term outcomes (simple cox regression) 

Outcomes

Comparisons

Hazard Ratio

95% CI

P value

Death

PPR to no remission

0.68

0.29-1.57

0.36

CPR to no remission

0.54

0.30-0.96

0.035

eGFR < 15

PPR to no remission

1.27

0.56-2.84

0.57

CPR to no remission

0.33

0.15-0.72

0.005

Dialysis or Transplant

PPR to no remission

1.31

0.55-3.08

0.54

CPR to no remission

0.41

0.19-0.92

0.03

SDI > 0

PPR to no remission

0.98

0.66-1.45

0.93

CPR to no remission

0.91

0.69-1.19

0.48

SDI > 3

PPR to no remission

1.43

0.80-2.53

0.23

CPR to no remission

0.838

0.52-1.34

0.46

Atherosclerotic Events

PPR to no remission

0.434

0.16-1.18

0.10

CPR to no remission

0.509

0.27-0.95

0.033

 Conclusion: Achieving CPR at 2 years, from the onset of LN, protects against comorbidities. PPR at 2 years doesn’t protect against comorbidities, thus physicians should aim to achieve CPR to prevent comorbidities in LN patients.


Disclosure: Z. Touma, None; M. Urowitz, None; J. Medina-Rosas, None; J. Su, None; D. Gladman, None.

To cite this abstract in AMA style:

Touma Z, Urowitz M, Medina-Rosas J, Su J, Gladman D. Do Patients with Lupus Nephritis Who Achieve Complete Proteinuria Recovery at 2 Years Have Better Long Term Outcomes Compared to Patients with Partial Proteinuria Recovery? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/do-patients-with-lupus-nephritis-who-achieve-complete-proteinuria-recovery-at-2-years-have-better-long-term-outcomes-compared-to-patients-with-partial-proteinuria-recovery/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-patients-with-lupus-nephritis-who-achieve-complete-proteinuria-recovery-at-2-years-have-better-long-term-outcomes-compared-to-patients-with-partial-proteinuria-recovery/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology